A european Phase III, multicentre, double-blind, randomised, monotherapy, 12-month study of Minalcipran for the treatment of the Fibromyalgia Syndrome

A european Phase III, multicentre, double-blind, randomised, monotherapy, 12-month study of Minalcipran for the treatment of the Fibromyalgia Syndrome

Hide study title
Status
Status :
Completed
Type of study
Phase III
Min. Age
18
Years old
Max. Age
71
Years old
Gender
All
Therapeutic area :
Central Nervous System
Disease :
Fibromyalgia
Study medication :
Milnacipran
Phase : Phase III
Start Date :
19 September 2006
End date :
02 October 2008
Study ID : F02207 GE 304
EudraCT/CTIS number : 2006-001230-41

Results

Public links :

Send by email